Nanox Imaging Ltd. (NASDAQ: NNOX) has entered into a distribution agreement with SOLME RC, S.A., a Costa Rica-based medical equipment distributor, to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The deal positions Nanox to penetrate Costa Rica's public healthcare system, as SOLME is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services. This agreement represents Nanox's third Latin American market this year, following earlier expansions into Argentina and Peru, underscoring the company's strategic focus on emerging markets where advanced imaging is often scarce.
The Nanox.ARC system is a cost-effective, 3D multi-source digital tomosynthesis imaging solution intended for ease of use and scalability. By partnering with SOLME, Nanox ensures local marketing, distribution, installation, training, and ongoing technical support. Commercialization will proceed after applicable regulatory registration, which includes an initial six-month proof-of-concept device registration period before full registration. This phased approach allows Nanox to demonstrate the system's value in a real-world setting, potentially accelerating adoption within Costa Rica's public health infrastructure.
For Nanox, this agreement is more than a distribution deal; it signifies progress in its broader vision to drive the world's transition to preventive healthcare. The company's integrated platform combines affordable imaging hardware, AI-based solutions, cloud-based software, remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. By targeting Costa Rica, where the CCSS dominates hospital services, Nanox gains a direct channel to a large patient population. This could lead to earlier diagnosis of chronic diseases, which aligns with the company's mission to enhance patient outcomes through accessible imaging.
The implications extend beyond Costa Rica. Success in this market could serve as a proof point for other Latin American countries and emerging economies, where the burden of chronic diseases is rising but access to advanced imaging remains limited. Nanox's ecosystem, including Nanox.AI for AI-based CT interpretation, Nanox.CLOUD for secure data management, and Nanox.MARKETPLACE for teleradiology services, offers a comprehensive solution that could be replicated across similar regions. The agreement also strengthens Nanox's competitive position against traditional imaging vendors by offering a lower-cost, scalable alternative that integrates AI and cloud capabilities.
Investors and industry observers may view this as a sign of Nanox's ability to execute on its global expansion strategy despite regulatory hurdles. The initial proof-of-concept period suggests a cautious but determined approach to market entry, balancing regulatory compliance with the need to demonstrate clinical and economic value. As Nanox continues to build its Latin American presence, the Costa Rica deal could pave the way for further partnerships and revenue growth. For healthcare providers in Costa Rica, the arrival of Nanox.ARC could mean improved diagnostic capabilities and better resource utilization, ultimately benefiting patients through earlier detection and treatment. The full press release can be viewed at https://ibn.fm/C77lJ, and the company's latest news is available at http://ibn.fm/NNOX. More information about BioMedWire is at https://www.BioMedWire.com.
